Treatment and hematopoietic SCT in aplastic anemia
Diagnosis of acquired aplastic anemia
Supportive care in severe and very severe aplastic anemia
Front-line immunosuppressive treatment of acquired aplastic anemia
Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor
Treatment of aplastic anaemia in elderly patients aged > 60 years
Haploidentical transplantation in patients with acquired aplastic anemia
Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)
Management of acquired aplastic anemia in children
Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning
Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression
Cord blood transplantation in aplastic anemia
Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?
Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision
Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)
Alternative donor SCT for the treatment of MHC Class II deficiency
PBSC mobilization in newly diagnosed patients with POEMS syndrome: outcomes and prognostic factors
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT
Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival
Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma
Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Societe Française de Greffe de Moelle-Therapie Cellulaire collaborative study
Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis
Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients
A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant
Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?
Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database
Suicide after hematopoietic SCT: the story of AG
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT
Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?
Response to: ‘Are there still reasons to believe that high-dose chemotherapy plays a role in breast cancer management?’
Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT
Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT
Successful syngeneic PBSC transplantation for a patient with refractory Evans syndrome
Donor selection for patients undergoing allogeneic hematopoietic SCT: assessment of the priorities of Canadian hematopoietic SCT physicians
Autologous cord blood transplantation in a child with stage 4 neuroblastoma
Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients